Latest imidazoles Stories
EAST HANOVER, N.J., June 5 /PRNewswire/ -- New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of ZometaÂ® (zoledronic acid) to first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12% (P=0.0179) compared with oral clodronate plus first-line chemotherapy(1).
THOUSAND OAKS, Calif., June 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with ZometaÂ® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study").
PARSIPPANY, N.J., May 1 /PRNewswire/ -- Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).(1) The study, presented at the American...
Study highlights: -- A study of nearly 4,000 heart failure patients finds that a larger dose of angiotensin receptor blockers (ARBs) works better than a smaller dose. -- The higher dose was associated with a 10.1 percent relative risk reduction (in the combined primary end-point of all-cause mortality and hospitalization for heart failure) versus the lower dose, mostly due to a reduction in the risk of heart failure hospitalizations.
WOODCLIFF LAKE, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc.
WOODCLIFF LAKE, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S.
SCHAUMBURG, Ill., Aug.
A major concern for people when having surgery is whether or not they will be safe while under anesthesia. New research is showing a new, potentially safer form of general anesthesia.
A team of Massachusetts General Hospital (MGH) physicians has developed a new general anesthetic that may be safer for critically ill patients.
WOODCLIFF LAKE, N.J., June 10 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S.
- The act of sweetening by admixture of some saccharine substance.